Completed PHASE1 INTERVENTIONAL 1-arm NCT01317927

A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies

A Phase I Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies

Sponsor: Spectrum Pharmaceuticals, Inc

Conditions Hematological Malignancy Solid Tumor

Updated 7 times since 2017 Last updated: Sep 21, 2015 Started: Dec 31, 2010 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hematological Malignancy and Solid Tumor and is currently completed. Spectrum Pharmaceuticals, Inc leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2024 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jan 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Spectrum Pharmaceuticals, Inc
Valerio Therapeutics

Data source: Spectrum Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Salt Lake City, United States